BMS ponders sales cuts due to Pargluva delay

Share this article:
Facing the reality that diabetes drug Pargluva (muraglitazar) won't be available for near-term promotion, Bristol-Myers Squibb is prepared to reduce its CV-metabolic sales force.
"The size of our current U.S. sales force was scaled to support a portfolio that we believed would be available for promotion," said Lamberto Andreotti, BMS executive vice president, president worldwide pharmaceuticals, during an investor meeting this week.
Pargluva was to be a centerpiece of that portfolio, but the FDA withheld approval in October, saying it needed more data from the company to examine the drug's risk for heart problems.
Cuts could come by early 2006, Andreotti said, if reps cannot be redistributed.
BMS has not stated whether it will pursue marketing approval for Pargluva. The product was not included among other compounds in a pipeline list provided for the investor meeting.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA lifts OncoMed partial hold

The FDA froze the clinical trial of anti-Fzd7 vantictumab in July over concern about "bone-related adverse events."

Research links estrogen and binge eating

Baylor College of Medicine researchers have found that an estrogen replacement suppressed binge-eating behavior among lab mice.

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.